To own Palantir Technologies, you need to believe its AI platforms can keep turning complex data work into mission critical software for both governments and enterprises. According to BlackGoat, an investor in the Simply Wall St Community, the real upside case hinges on AIP, Gotham and Foundry staying essential as AI adoption broadens. The short term swing factor is execution on large deployments like the NHS and U.S. commercial deals, while the main risk remains a rich valuation that gives the stock little room for revenue or margin disappointment.
Operationally, the extended NHS Federated Data Platform contract and U.S. commercial revenue surpassing U.S. government income both point to deeper product embedding rather than one off projects. That supports the story of a maturing software platform but does not remove key near term risks. Reliance on sizeable public sector work, heavy competition in AI software and very high market expectations, highlighted by BlackGoat, still leave little tolerance for slower contract wins or rising costs.
The NHS extension through 2029 is the announcement that matters most here because it directly ties Palantir Technologies to one of the largest healthcare data programs in the world. This decision keeps the company in place on a multi year, sensitive workload where uptime, privacy controls and measurable operational outcomes are all constantly scrutinized. That type of reference account can matter more to future deals than to any single quarter.
For catalysts, that contract underpins the argument that AIP and Foundry are not just analytics tools but operational systems that run real workflows in hospitals and clinics. It also highlights the flip side that BlackGoat stresses. When a business trades on high expectations and premium P/E levels, execution on flagship projects like the NHS and major U.S. commercial customers becomes the key test for sustaining the growth narrative investors are paying for.
BlackGoat’s narrative reaches its fair value of $171.06 for Palantir Technologies by pairing 36.0% annual revenue growth with a future profit margin of 40.0%. It then applies the same premium P/E logic used in the earlier DCF to reflect what the market might pay for those earnings.
Uncover why Palantir Technologies' fair value indicates a 9% potential upside to its current price, which could narrow quickly.
Some of the most optimistic analysts frame the NHS extension as a possible accelerator for Palantir Technologies on top of an already aggressive story. Before this news, the bullish group was pencilling in revenue climbing to about US$31.9b and earnings near US$14.3b by 2029. Those numbers assume years of strong execution, so fresh contracts like the NHS decision could prompt revisions, both up and down, as different viewpoints react and you weigh which narrative feels more realistic.
Explore 22 other Palantir Technologies fair value estimates, including one that suggests as much as 104% upside from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Once you have formed a view on Palantir Technologies, it can help to compare that thesis with a few other opportunities that share some of the qualities you care about, whether that is income strength, balance sheet resilience, or a mix of quality and reasonable pricing.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com